ArticleThe European respiratory journal2021
Prediction of anti-tuberculosis treatment duration based on a 22-gene transcriptomic model.
Article in The European respiratory journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04783727 (Personalized Therapy Durations Defined by the Blood RNA-based Model for Individualizing Treatment in Multidrug-Resistant Tuberculosis), which is not on this map. Cited by 31 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Personalized Therapy Durations Defined by the Blood RNA-based Model for Individualizing Treatment in Multidrug-Resistant Tuberculosis
Who cites it
31 citing papers in PubMed, 3 syntheses or guidelines pooled it, 56 citations in OpenAlex.
- CXCL9/CXCL10 as biomarkers the monitoring of treatment responses in Pulmonary TB patients: a systematic review and meta-analysis.BMC infectious diseases · 2024Pooled it
- Treatment of MDR, Pre-XDR, XDR, and Rifampicin-Resistant Tuberculosis or in Case of Intolerance to at Least Rifampicin in Austria, Germany, and Switzerland.Respiration; international review of thoracic diseases · 2024Guideline
- Gene signature discovery and systematic validation across diverse clinical cohorts for TB prognosis and response to treatment.PLoS computational biology · 2023Pooled it
- Blood transcriptomic signatures predict poor outcomes in drug-susceptible pulmonary tuberculosis in Brazil.American journal of respiratory and critical care medicine · 2026Article
- Host response biomarkers of tuberculosis recurrence and treatment failure.Communications medicine · 2026Article
- Ly6GeLife · 2026Article
- Genetic ancestry proportion influences risk of adverse events from tuberculosis treatment in Brazil.Human genetics · 2026Observational
- Host-response biomarkers for precision tuberculosis: from immune transcriptomic signatures to clinical risk stratification.Frontiers in cell and developmental biology · 2026Review
- PD-L1-centric whole blood-based immune signature profiles of tuberculosis patients during therapy.Frontiers in immunology · 2026Article
- Harnessing the gut microbiome to combat tuberculosis: a technological and clinical review.Frontiers in cellular and infection microbiology · 2026Review
- Host- and pathogen-related determinants of pulmonaryEuropean respiratory review : an official journal of the European Respiratory Society · 2026Review
- Deep immune profiling delineates hallmarks of disease heterogeneity in extrapulmonary tuberculosis.Nature communications · 2025Article
- Blood transcriptomic signatures predict poor treatment outcomes in drug-susceptible pulmonary TB in Brazil.medRxiv : the preprint server for health sciences · 2025Article
- Molecular Indicator for Distinguishing Multi-drug-Resistant Tuberculosis from Drug Sensitivity Tuberculosis and Potential Medications for Treatment.Molecular biotechnology · 2025Article
- Analysis of gene expression in patients prior to TB treatment to identify those associated with pyrazinamide-hepatotoxicity.IJTLD open · 2025Article
- Distinguish active tuberculosis with an immune-related signature and molecule subtypes: a multi-cohort analysis.Scientific reports · 2024Article
- Artificial intelligence in tuberculosis: a new ally in disease control.Breathe (Sheffield, England) · 2024Article
- Advances in tuberculosis biomarkers: unravelling risk factors, active disease and treatment success.Breathe (Sheffield, England) · 2024Article
- Developing biomarker assays to accelerate tuberculosis drug development: defining target product profiles.The Lancet. Microbe · 2024Review
- Multidrug-resistant tuberculosis.Nature reviews. Disease primers · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors at 18 institutions in 10 countries.
Funding
Abstract
backgroundThe World Health Organization recommends standardised treatment durations for patients with tuberculosis (TB). We identified and validated a host-RNA signature as a biomarker for individualised therapy durations for patients with drug-susceptible (DS)- and multidrug-resistant (MDR)-TB.
methodsAdult patients with pulmonary TB were prospectively enrolled into five independent cohorts in Germany and Romania. Clinical and microbiological data and whole blood for RNA transcriptomic analysis were collected at pre-defined time points throughout therapy. Treatment outcomes were ascertained by TBnet criteria (6-month culture status/1-year follow-up). A whole-blood RNA therapy-end model was developed in a multistep process involving a machine-learning algorithm to identify hypothetical individual end-of-treatment time points.
results50 patients with DS-TB and 30 patients with MDR-TB were recruited in the German identification cohorts (DS-GIC and MDR-GIC, respectively); 28 patients with DS-TB and 32 patients with MDR-TB in the German validation cohorts (DS-GVC and MDR-GVC, respectively); and 52 patients with MDR-TB in the Romanian validation cohort (MDR-RVC). A 22-gene RNA model (TB22) that defined cure-associated end-of-therapy time points was derived from the DS- and MDR-GIC data. The TB22 model was superior to other published signatures to accurately predict clinical outcomes for patients in the DS-GVC (area under the curve 0.94, 95% CI 0.9-0.98) and suggests that cure may be achieved with shorter treatment durations for TB patients in the MDR-GIC (mean reduction 218.0 days, 34.2%; p<0.001), the MDR-GVC (mean reduction 211.0 days, 32.9%; p<0.001) and the MDR-RVC (mean reduction of 161.0 days, 23.4%; p=0.001).
conclusionBiomarker-guided management may substantially shorten the duration of therapy for many patients with MDR-TB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.